Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcutis Enjoys Seborrheic Dermatitis Win But Experts Itching For Psoriasis Approval

Executive Summary

The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.

You may also be interested in...



Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Jazz Pins Sativex US Hopes On Two Advanced Studies After First MS Spasticity Trial Flunks

The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.

Kezar’s Lead Asset Bounces Back With Lupus Win

Kezar’s lead asset zetomipzomib has demonstrated clinical significance in a mid-stage lupus trial just weeks after a disappointment in myositis but more robust data are needed for the first-in-class selective immunoproteasome inhibitor. 

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel